高风险和低患病率的疾病:梅特福林的毒性
Daniel Rivera1, Nancy Onisko1, James Dazhe Cao1
1Department of Emergency Medicine, UT Southwestern, Dallas, TX, USA.
The American journal of emergency medicine
|July 30, 2023
概括
甲胺毒性虽然很少见,但是一种严重的疾病,死亡率高. 早期识别和积极的治疗,包括对甲胺相关乳酸症 (MALA) 的血液透析,对于患者的生存至关重要.
科学领域:
- 毒理学 毒理学 毒理学
- 紧急医疗 紧急医疗
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲胺是一种被广泛处方的抗糖尿病药物.
- 甲胺毒性涵盖了一系列疾病,包括MALA,MILA和MULA.
- 与甲胺相关的乳酸性化症 (MALA) 是最严重的形式,死亡率高达50%.
研究的目的:
- 审查诊断,复苏和管理在急诊室的甲福明毒性.
- 为突出紧急诊所医生管理甲胺毒性的关键考虑因素.
主要方法:
- 审查目前关于甲福明毒性的证据.
- 讨论诊断挑战和临床表现.
- 管理策略的概述,包括液体复苏和血液透析.
主要成果:
- 甲胺毒性呈现非特异性症状,实验室发现高乳酸含量与离子间隙代谢酸化.
- 在没有甲福林水平的情况下,区分MALA,MILA和MULA可能具有挑战性.
- 包括血液透析在内的积极治疗对MALA至关重要.
结论:
- 了解甲福明的毒性对于急诊医生来说至关重要.
- 及时诊断和管理可以改善梅特福林毒性患者的治疗结果.
- 建议对MALA进行早期血液透析和专家咨询.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
234
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
234
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208
Diabetes: Symptoms, Diagnosis, and Complications
593
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
593
Oral Hypoglycemic Agents: Sulfonylureas
245
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
245
Hypoglycemia and Glucagon
301
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
301


